Background Overall, up to one-third of epilepsy patients have drug-resistant epilepsy.
However, there was previously no meta-analysis to support the guidelines for broad …

Abstract Objective Randomized controlled trials (RCTs) in epilepsy for drug treatments are
plagued by high costs. One potential remedy is to reduce placebo response via better …

Epilepsy is a chronic condition that consists of a transient disorder of brain function
manifested by recurrent and unprovoked seizures affecting approximately 50 million people …

Background: Levetiracetam (LEV) is approved for treating epilepsy. The current evidence
shows that LEV can cause behavioral problems such as depression. It is well-known that …

左乙拉西坦(LEV) 是第二代广谱抗癫痫药物, 具有起效快, 半衰期短, 疗效确切, 耐受性好,
药物相互作用少等优点. 为提高LEV 的临床效果, 减少不良反应的发生, 应对儿童, 妊娠期妇女 …

Epilepsy is a chronic disease caused by sudden abnormal discharge of brain neurons,
leading to transient brain dysfunction. Levetiracetam, developed by the UCB company in …

Introduction: One of the drugs that are added to common treatments in drug-resistant
epilepsy is levetiracetam. Objectives: In this study, the effect of levetiracetam and …

One third of the overall epilepsy population are estimated to be a drug refractory epilepsy
(DRE), defined as the patients who failed to control seizure reduction, even tried two or more …

Levetiracetam (LEV) is the second generation of broad-spectrum anti-epileptic drug. LEV
has the advantages of rapid absorption, short half-life, precise efficacy, good tolerance and …

Background: Epilepsy is a neurological disorder characterized by recurrent seizures, and
about one-third of patients do not respond to a single antiepileptic drug (AED) …